MedTrace Logo

Efficacy Study in Removing Excess Iron From the Heart

NCT00105495 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-01-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether deferiprone has superior efficacy in removing excess iron from the heart when compared with deferoxamine.

Conditions

  • Thalassemia Major
  • Hemosiderosis

Interventions

DRUG

Ferriprox (deferiprone)

DRUG

Desferal (deferoxamine)

Sponsors & Collaborators

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • Renzo Galanello, M.D. · Ospedale Regionale Microcitemie, Cagliari, Italy

  • Antonio Piga, M.D. · Dipartimento di Scienze Pediatriche e Dell'Adolescenza, University of Turin, Turin, Italy

  • Markissia Karagiorga, M.D. · Aghia Sophia Children's Hospital, Athens, Greece

  • Vassilis Ladis, M.D. · 1st Department of Pediatrics, Athens University, Aghia Sophia Children's Hospital, Athens, Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Completion
2004-10-31

Countries

  • Greece
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00105495 on ClinicalTrials.gov